Who are AN2690 Topical Solution, 5%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NAFT500 (pediatric), Tavaborole 5% Topical Solution, Terbinafine Tablets, Jublia®, Lotrimin Ultra®, NAFT600 (pediatric).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/an2690-topical-solution-5.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

AN2690 Topical Solution, 5% — Competitive Intelligence Brief

AN2690 Topical Solution, 5% (AN2690 Topical Solution, 5%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antifungal (squalene epoxidase inhibitor). Area: Dermatology / Infectious Disease.

phase 3 Topical antifungal (squalene epoxidase inhibitor) Squalene epoxidase Dermatology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

AN2690 Topical Solution, 5% (AN2690 Topical Solution, 5%) — Pfizer. AN2690 is a topical antifungal that inhibits fungal squalene epoxidase, disrupting ergosterol synthesis in the fungal cell membrane.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AN2690 Topical Solution, 5% TARGET	AN2690 Topical Solution, 5%	Pfizer	phase 3	Topical antifungal (squalene epoxidase inhibitor)	Squalene epoxidase
NAFT500 (pediatric)	NAFT500 (pediatric)	Merz North America, Inc.	marketed	Allylamine antifungal	Squalene epoxidase
Tavaborole 5% Topical Solution	Tavaborole 5% Topical Solution	Pfizer	marketed	Benzoxaborole antifungal	Squalene epoxidase
Terbinafine Tablets	Terbinafine Tablets	Oregon Health and Science University	marketed	Allylamine antifungal	Squalene epoxidase
Jublia®	Jublia®	Dong-A ST Co., Ltd.	marketed	Azole antifungal	Squalene epoxidase (fungal)
Lotrimin Ultra®	Lotrimin Ultra®	Sun Pharmaceutical Industries, Inc.	marketed	Allylamine antifungal	Squalene epoxidase
NAFT600 (pediatric)	NAFT600 (pediatric)	Merz North America, Inc.	marketed	Topical antifungal (allylamine)	Squalene epoxidase (fungal)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antifungal (squalene epoxidase inhibitor) class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AN2690 Topical Solution, 5% — Competitive Intelligence Brief. https://druglandscape.com/ci/an2690-topical-solution-5. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab